SUMMARY To determine if loperamide is effective and safe in treating watery diarrhoea, we randomly assigned 50 adult expatriates in Bangladesh with more than three unformed stools in the previous 24 hours and illness of less than 72 hours to receive loperamide or a placebo. On entry into the five day study patients took two capsules (one loperamide capsule=2 mg) and one after each unformed stool up to a maximum of eight per day. The groups did not significantly differ in pretreatment features or pathogens identified. Mean number of stools on study day 1 was 2.6 in the loperamide group and 4.0 in the placebo group (p=0.035); on day 2 it was 1.3 versus 3-4 (p<0.001). Differences in stool frequencies during the final three study days, or proportion of patients with cramps, nausea, or vomiting on any study day, were not significant. No serious side effects occurred in either group. We conclude that loperamide, by decreasing stool frequency during the early part of illness, may have a role in the symptomatic treatment of this self-limiting disease. In this study we examined the effectiveness of loperamide compared with placebo in treating watery diarrhoea among expatriates in Bangladesh."'
Every year about 16 million people travel from industrialised to developing countries, and one third will develop diarrhoea.' In one study 20% of affected travellers were bedridden, and 40% had to alter their schedules.
This considerable morbidity has prompted efforts to identify symptomatic therapies, which are of four general types. Oral rehydration solutions replace fluid loss but do not influence duration of illness or stool frequency. Some antimicrobial agents decrease the duration of illness and alleviate symptoms.3 4 Adsorbants such as bismuth salts, although effective, are impractical because of the large volumes required.sx Lastly the synthetic opiate like antimotility (and possibly antisecretory) agents diphenoxylate and loperamide hydrochloride7 are widely used despite few controlled trialsbs and concern about their use in patients with shigellosis.9
In this study we examined the effectiveness of loperamide compared with placebo in treating watery diarrhoea among expatriates in Bangladesh."' Address for correspondence: F P 1. van Patients who had Shigella isolated from their stool were withdrawn from the study. No antimicrobial therapy, or other adjunctive therapy, were provided to patients with other enteropathogens.
LABORATORY METHODS
A wet mount of faeces was examined microscopically for ova, cysts, and trophozoites of parasites, and the number of red and white blood cells. If cysts or trophozoites were initially absent, the sediment was examined after formol-ether concentration.`" Stool was cultured for Salmonella spp, Shigella spp, Vibrio cholerae, Campylobacter, and Escherichia coli using standard methods.'2 Colonies of E coli were tested for the production of heat labile toxin (LT) by the Chinese hamster ovary cell assay'3 and for heat stable toxin (ST) by the infant mouse assay.'4 Rotavirus was diagnosed using an enzymelinked immunosorbent assay without blocking.'5
STATISTICAL ANALYSIS
The significance in the difference in means was tested using Student's t test. Differences in mean number of stools was tested using a one-tailed test, on the assumption that loperamide might decrease, but could not increase, stool frequency. All other means were tested using a two-tailed test. Differences in proportions were compared using the x2 test. All testing was done using Stat-Pac software (Walonick Associates, Minneapolis, Minn, USA).
The study was approved by the Ethical and Research Review Committees of the ICDDR, B.
Results
Fifty patients from 11 North American and West European countries were enrolled; 27 received loperamide and 23 placebo. Three loperamide treated patients withdrew before the study's completion (two after day 2, the third after day 4); similarly four placebo treated patients withdrew (three after day 2 and the fourth after day 4). For both groups the results before withdrawal were included. Reasons for withdrawal in the loperamide group were lack of improvement in diarrhoea in one patient, severe cramping in a second patient, and infection with Shigella flexneri in a third. Three placebo treated patients withdrew because of a lack of improvement in diarrhoea, and the fourth was infected with Shigella flexneri. One Shigella dysenteriae type 1 infected patient in the loperamide group continued in the study for all five days. There were no significant differences in characteristics of the groups on admission ( Table 1) . None of the patients had clinical signs of dehydration. Of the 27 patients in the loperamide group nine submitted three stool samples, 12 two samples, and six one sample; among the 23 placebo patients 15 submitted three samples, six two samples, and two one sample. Enteric pathogens identified from any of these samples are shown in Table 2 .
The Figure shows that loperamide patients had significantly fewer stools on study day 1 and 2 than did placebo treated patients. In loperamide treated patients during the five consecutive study days cramps were present in 70%, 65%, 36%, and 16% of the patients; in placebo treated patients the corresponding figures were 78%, 63%, 44%, 40%, and van Loon, Bennish, Speelman, and Butler 
